Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Treating AML: Does Facility Type Matter?

Am J Hematol; ePub 2017 Jun 1; Bhatt, et al

Patients with acute myeloid leukemia (AML) who received their initial therapy at academic centers experienced lower short-term mortality and better long-term overall survival, according to an analysis involving nearly 61,000 individuals.

Participants were initially treated between 2003 and 2011 at academic or nonacademic centers. Investigators compared 1-month mortality and long-term overall survival. Among the results:

  • Patients treated at academic centers averaged 62 years of age; average age of those seen at nonacademic centers was 70.
  • The academic center group comprised more ethnic minorities, as well as those with a lower level of education.
  • They also had a lower comorbidity score; a different income and insurance profile; and tended to receive chemotherapy and transplant more often.
  • 1-month mortality among patients treated at academic centers was 16%, vs 29% in the group treated at nonacademic centers.
  • 5-year overall survival was 25% and 15%, respectively.

The authors called for further research to uncover the underlying reasons for the disparity.

Citation:

Bhatt V, Shostrom V, Giri S, et al. Early mortality and overall survival of acute myeloid leukemia based on facility type. [Published online ahead of print June 1, 2017]. Am J Hematol. doi:10.1002/ajh.24767.

Must Reads in AML

Immune system changes play a role in AML relapse, Christopher MJ et al. N Engl J Med. 2018 Oct 31. doi: 10.1056/NEJMoa1808777.

Venetoclax plus HMA studied in AML, DiNardo C et al. Blood. 2018 Oct 25. doi: 10.1182/blood-2018-08-868752.

T cell infusion effective in PML, Muftuoglu M et al. N Engl J Med. 2018 Oct 11;379:1443-51

Higher AML, MDS risk linked to autotransplants, Radivoyevitch T et al. Leuk Res. 2018 Jul 19. pii: S0145-2126(18)30160-7

Tibsovo for AML with IDH1 mutation, FDA approves first targeted treatment for patients with relapsed or refractory acute myeloid leukemia who have a certain genetic mutation, FDA press release